Abstract
The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.
Similar content being viewed by others
References
Legler JM, Ries LA, Smith MA et al (1999) Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382–1390. doi:10.1093/jnci/91.16.1382
Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, Pa, pp 2100–2160
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
DeAngelis LM (2005) Chemotherapy for brain tumors—a new beginning. N Engl J Med 352(10):1036–1038. doi:10.1056/NEJMe058010
Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6(12):937–944. doi:10.1016/S1470-2045(05)70432-0
Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379. doi:10.1016/S0090-3019(99)00103-2
Kowalczuk A, Macdonald RL, Amidei C et al (1997) Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:1028–1038. doi:10.1097/00006123-199711000-00004
Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extentof resection, and survival. J Neurosurg 95:190–198
Stupp R, Mason WP, Van Den Bent MJ, et al (2004) Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain and RT Groups and NCIC Clinical Trials Group [Abstract]. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 22, No 14S (July 15 Supplement) 2
Nieder C, Adam M, Molls M et al (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60(3):181–193. doi:10.1016/j.critrevonc.2006.06.007
Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012. doi:10.1016/S0140-6736(95)90755-6
Pinsker M, Lumenta C (2001) Experience with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43–47. doi:10.1055/s-2002-19477
Olivi A, Grossman SA, Tatter S et al (2003) Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 21:1845–1849. doi:10.1200/JCO.2003.09.041
Franceschi E, Omuro AM, Lassman AB et al (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476. doi:10.1002/cncr.21564
Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16(5):1117–1121
Chamberlain MC, Tsao-Wei DD (2004) Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 15, 100(6):1213–1220
Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786. doi:10.1200/JCO.2004.06.181 Erratum in: J Clin Oncol 2005 23. 1:248
Fine HA, Wen PY, Maher EA et al (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21(12):2299–2304. doi:10.1200/JCO.2003.08.045
Kayat D, Lokiec F, Bizzarri JP et al (1987) Phase I clinical study of the new amino acid-linked nirtrosourea, S 10036, administered in a weekly schedule. Cancer Res 47:6782–6785
Kleeberg UR, Engel E, Israels P et al (1995) Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 5(3):195–200. doi:10.1097/00008390-199506000-00009
Silvani A, Lamperti E, Gaviani P et al (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143–151. doi:10.1007/s11060-007-9427-y
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216. doi:10.1093/jnci/92.3.205
Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. doi:10.2307/2281868
Curran WJ, Scott JB, Horton JS et al (1993) Recursive partition analysis of prognostic factors in three radiation therapy and oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710. doi:10.1093/jnci/85.9.704
Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71(5):1372–1380. doi:10.1016/j.ijrobp.2007.11.068
Ali SA, McHayleh WM, Ahmad A et al (2008) Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 109(2):268–272. doi:10.3171/JNS/2008/109/8/0268
Bokstein F, Shpigel S, Blumenthal DT (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112(10):2267–2273. doi:10.1002/cncr.23401
Norden AD, Young GS, Setayesh K (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787. doi:10.1212/01.wnl.0000304121.57857.38
Fazeny-Dorner B et al (2003) Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 14:437–442. doi:10.1097/00001813-200307000-00008
Frenay M, Giroux B, Khoury S et al (1991) Phase II study of fotemustine in recurrent sopratentorial malignant gliomas. Eur J Cancer 27(7):852–856
Scoccianti S, Detti B, Iannalfi A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institutional experience. Anti-Cancer Drug 19:6613–6620
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fabrini, M.G., Silvano, G., Lolli, I. et al. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92, 79–86 (2009). https://doi.org/10.1007/s11060-008-9739-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-008-9739-6